Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 1. Michael acceptor structure-activity studies.
The structure-based design, chemical synthesis, and biological evaluation of peptide-derived human rhinovirus (HRV) 3C protease (3CP) inhibitors are described. These compounds incorporate various Michael acceptor moieties and are shown to irreversibly bind to HRV serotype 14 3CP with inhibition activities (kobs/[I]) ranging from 100 to 600 000 M-1 s-1. These inhibitors are also shown to exhibit antiviral activity when tested against HRV-14-infected H1-HeLa cells with EC50's approaching 0.50 microM. Extensive structure-activity relationships developed by Michael acceptor alteration are reported along with the evaluation of several compounds against HRV serotypes other than 14. A 2.0 A crystal structure of a peptide-derived inhibitor complexed with HRV-2 3CP is also detailed.
Agouron Pharmaceuticals, Inc., 3565 General Atomics Court, San Diego, California 92121, USA.
P S
PS
Dragovich
S E
SE
Webber
R E
RE
Babine
S A
SA
Fuhrman
A K
AK
Patick
D A
DA
Matthews
C A
CA
Lee
S H
SH
Reich
T J
TJ
Prins
J T
JT
Marakovits
E S
ES
Littlefield
R
R
Zhou
J
J
Tikhe
C E
CE
Ford
M B
MB
Wallace
J W
JW
Meador
R A
RA
Ferre
E L
EL
Brown
S L
SL
Binford
J E
JE
Harr
D M
DM
DeLisle
S T
ST
Worland
D000086042:3C Viral Proteases; D000818:Animals; D000998:Antiviral Agents / Q000138:chemical synthesis / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology; D001665:Binding Sites; D002461:Cell Line, Transformed; D018360:Crystallography, X-Ray; D003546:Cysteine Endopeptidases / Q000737:chemistry / Q000378:metabolism*; D015853:Cysteine Proteinase Inhibitors / Q000138:chemical synthesis / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology; D015195:Drug Design; D004355:Drug Stability; D006367:HeLa Cells; D006801:Humans; D009842:Oligopeptides / Q000138:chemical synthesis / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology; D011487:Protein Conformation; D051381:Rats; D017207:Rats, Sprague-Dawley; D012229:Rhinovirus / Q000187:drug effects* / Q000201:enzymology; D013329:Structure-Activity Relationship; D014764:Viral Proteins
D000998:Antiviral Agents; D015853:Cysteine Proteinase Inhibitors; D009842:Oligopeptides; D014764:Viral Proteins; D003546:Cysteine Endopeptidases; D000086042:3C Viral Proteases